{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:03:25Z","timestamp":1790013805064,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypopharyngeal and laryngeal squamous cell carcinoma (SCC) account for 25\u201330% of head and neck SCC. Total laryngectomy, while effective, compromises the quality of life. Immune checkpoint inhibitors such as Camrelizumab offer potential in laryngeal preservation. The study investigated Camrelizumab combined with TP regimen as a neoadjuvant therapy for laryngeal preservation in advanced hypopharyngeal and laryngeal SCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective study was conducted at Sun Yat-sen University Cancer Center on patients diagnosed with locally advanced SCC of the hypopharynx and larynx from October 1, 2019, to October 25, 2022. The efficacy of a first-line treatment combining Camrelizumab (200\u00a0mg) and TP regimen (Albumin-bound paclitaxel at 260\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and Cisplatin at 60\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) was evaluated using RECIST 1.1 criteria. Outcomes included overall survival (OS), progression-free survival (PFS), laryngectomy-free survival (LFS), and response rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 71 included patients, the median age was 60.7\u00a0years. Post the first-line treatment, 90.1% demonstrated an overall response. The one-year and two-year OS rates were 91.5% and 84.3%, respectively. One-year and two-year PFS rates were 92.9% and 83.9%, respectively, with LFS at 85.6% and 73.2%. The initial T4 stage as significantly associated with reduced OS and LFS. Skin reaction was the predominant adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Camrelizumab-TP regimen demonstrated promising results for advanced hypopharyngeal\/laryngeal SCC patients, exhibiting high response rates, OS, and LFS, positioning it as a potential primary option for laryngeal preservation. Further comprehensive, randomized controlled studies are imperative to validate these initial observations and elucidate the regimen's full clinical efficacy in optimizing laryngeal outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-023-03579-0","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T11:03:27Z","timestamp":1707995007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma"],"prefix":"10.1007","volume":"73","author":[{"given":"Jin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"3","key":"3579_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3579_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR et al (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6(1):92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3","journal-title":"Nat Rev Dis Primers"},{"key":"3579_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijsu.2018.09.011","volume":"58","author":"AT Bui","year":"2018","unstructured":"Bui AT, Yong Ji KS, Pham CT et al (2018) Longitudinal evaluation of quality of life in laryngeal cancer patients treated with surgery. Int J Surg 58:65\u201370. https:\/\/doi.org\/10.1016\/j.ijsu.2018.09.011","journal-title":"Int J Surg"},{"issue":"3","key":"3579_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijrobp.2015.03.004","volume":"92","author":"S Grover","year":"2015","unstructured":"Grover S, Swisher-Mcclure S, Mitra N et al (2015) Total laryngectomy versus larynx preservation for t4a larynx cancer: patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys 92(3):594\u2013601. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.03.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"3579_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2017.75.7385","volume":"36","author":"AA Forastiere","year":"2018","unstructured":"Forastiere AA, Ismaila N, Lewin JS et al (2018) Use of larynx-preservation strategies in the treatment of laryngeal cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 36(11):1143\u20131169. https:\/\/doi.org\/10.1200\/JCO.2017.75.7385","journal-title":"J Clin Oncol"},{"issue":"24","key":"3579_CR6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","volume":"324","author":"GT Wolf","year":"1991","unstructured":"Wolf GT, Fisher SG, Hong WK et al (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324(24):1685\u20131690","journal-title":"N Engl J Med"},{"issue":"22","key":"3579_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa031317","volume":"349","author":"AA Forastiere","year":"2003","unstructured":"Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091\u20132098","journal-title":"N Engl J Med"},{"issue":"19","key":"3579_CR8","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1002\/cncr.32292","volume":"125","author":"SA Patel","year":"2019","unstructured":"Patel SA, Qureshi MM, Dyer MA et al (2019) Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer. Cancer 125(19):3367\u20133377. https:\/\/doi.org\/10.1002\/cncr.32292","journal-title":"Cancer"},{"issue":"5","key":"3579_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/lary.30279","volume":"133","author":"A Eita","year":"2023","unstructured":"Eita A, Mohamed N, Rybkin A et al (2023) Outcomes for organ preservation with chemoradiation therapy for t4 larynx and hypopharynx cancer. Laryngoscope 133(5):1138\u20131145. https:\/\/doi.org\/10.1002\/lary.30279","journal-title":"Laryngoscope"},{"issue":"10","key":"3579_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/annonc\/mdy332","volume":"29","author":"A Dietz","year":"2018","unstructured":"Dietz A, Wichmann G, Kuhnt T et al (2018) Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol 29(10):2105\u20132114. https:\/\/doi.org\/10.1093\/annonc\/mdy332","journal-title":"Ann Oncol"},{"issue":"1","key":"3579_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C et al (2023) Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther 8(1):320. https:\/\/doi.org\/10.1038\/s41392-023-01522-4","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"3579_CR12","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1084\/jem.20182395","volume":"216","author":"JM Fritz","year":"2019","unstructured":"Fritz JM, Lenardo MJ (2019) Development of immune checkpoint therapy for cancer. J Exp Med 216(6):1244\u20131254. https:\/\/doi.org\/10.1084\/jem.20182395","journal-title":"J Exp Med"},{"issue":"10","key":"3579_CR13","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","volume":"28","author":"A Obradovic","year":"2022","unstructured":"Obradovic A, Graves D, Korrer M et al (2022) Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer. Clin Cancer Res 28(10):2094\u20132109. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3570","journal-title":"Clin Cancer Res"},{"key":"3579_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fonc.2020.00268","volume":"10","author":"VC Kok","year":"2020","unstructured":"Kok VC (2020) Current understanding of the mechanisms underlying immune evasion from PD-1\/PDL-1 immune checkpoint blockade in head and neck cancer. Front Oncol 10:268. https:\/\/doi.org\/10.3389\/fonc.2020.00268","journal-title":"Front Oncol"},{"issue":"10167","key":"3579_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393(10167):156\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8","journal-title":"Lancet"},{"issue":"10","key":"3579_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y et al (2021) Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326(10):916\u2013925. https:\/\/doi.org\/10.1001\/jama.2021.12836","journal-title":"JAMA"},{"issue":"1","key":"3579_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41392-022-01213-6","volume":"8","author":"Y Ma","year":"2023","unstructured":"Ma Y, Cao J, Zhang Y et al (2023) Phase I study of camrelizumab in patients with advanced solid tumors. Signal Transduct Target Ther 8(1):47. https:\/\/doi.org\/10.1038\/s41392-022-01213-6","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"3579_CR18","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","volume":"28","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wu B, Peng G et al (2022) Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial. Clin Cancer Res 28(15):3268\u20133276. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0666","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3579_CR19","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"W-T Ju","year":"2022","unstructured":"Ju W-T, Xia R-H, Zhu D-W et al (2022) A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun 13(1):5378. https:\/\/doi.org\/10.1038\/s41467-022-33080-8","journal-title":"Nat Commun"},{"issue":"10408","key":"3579_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S et al (2023) Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402(10408):1133\u20131146. https:\/\/doi.org\/10.1016\/S0140-6736(23)00961-3","journal-title":"Lancet"},{"issue":"14","key":"3579_CR21","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1200\/JCO.22.01450","volume":"41","author":"X Ding","year":"2023","unstructured":"Ding X, Zhang W-J, You R et al (2023) Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm. Phase II Study J Clin Oncol 41(14):2571\u20132582. https:\/\/doi.org\/10.1200\/JCO.22.01450","journal-title":"Phase II Study J Clin Oncol"},{"issue":"1","key":"3579_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1186\/s12885-022-10306-y","volume":"22","author":"X Luo","year":"2022","unstructured":"Luo X, Huang X, Luo J et al (2022) Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial. BMC Cancer 22(1):1235. https:\/\/doi.org\/10.1186\/s12885-022-10306-y","journal-title":"BMC Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03579-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T02:02:57Z","timestamp":1709949777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03579-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["3579"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03579-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"13 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All contributors have reviewed and endorsed the final manuscript, which remains unpublished and is not under consideration for publication elsewhere, either in part or in entirety, in any language. The authors affirm the absence of any conflicting interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Research Ethics Committee of Sun Yat-sen University Cancer Center (B2022-628\u201301).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"54"}}